Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
SAB Biotherapeutics, Inc.
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
May 25, 2026
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
May 24, 2026
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
May 23, 2026
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
May 22, 2026
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
May 18, 2026
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
May 17, 2026
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
May 17, 2026
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 17, 2026
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
May 16, 2026